Is it time that board and upper management seek more innovation over conventional approaches in their business models? Even on speculative stock levels? As we continue to see the SP erode parallel to funding the above questions become a reality for the now as a view towards the future. Example, in recent times (last 5 years or so), more and more companies at blue stock and revenue producing levels have opted of project identification funding allocation (CR) then application. The point here is this: the ptx-100 project was announced as to enter the clinical arena last year, yet is imminent to commence Q1/2 this year...., Again, is time for at least some board and upper management at a speculative stock level to be more innovative rather than conventional in timeline funding of their respective business model? (IMO), yes.
PTX Price at posting:
6.6¢ Sentiment: Hold Disclosure: Held
